Bold Moves

Drew Price (Oncology)



Pfizer's Bold Moves

Bringing scientific breakthroughs to the global patient community

Pfizer's growth strategy is driven by five “bold moves” that help us deliver breakthroughs for patients and create value for shareholders and other stakeholders. In this section, we invite you to learn more about how applying our bold moves across our operating units and functions gives us confidence that SCIENCE WILL WINTM the battle against disease.

Unleash the power of our people

We have built an inclusive, engaging work environment that recognizes and rewards both performance and leadership and empowers all colleagues to bring their best selves to work for the benefit of patients.

Deliver first-in-class science

We aim to create and source the best science in the world. We bring forward only our most promising and transformational products within our six therapeutic areas – with a focus on getting them to patients as quickly as possible, while never compromising quality or safety.

Transform our go-to-market model

We are partnering with others to address the patient affordability challenge by exploring new, flexible payment approaches, including value-based agreements and being bold in how we expand access to our medicines.

Win the digital race in pharma

We are using big data and such digital technologies as machine learning and artificial intelligence to expedite the drug discovery and development process and to enhance patient experiences and outcomes.

Lead the conversation

We engage with policymakers and other stakeholders to advocate for policies that allow innovation to flourish while ensuring patient access to the latest therapies – all while communicating the value our science brings to society.

Focus Areas

Explore some of the top stories from 2020 


COVID-19: The path to a vaccine

Pfizer emerged as an early leader in the fight against COVID-19, advancing a clear vision for industry-wide collaboration while increasing investments in breakthrough science and global manufacturing. Pfizer and BioNTech SE blazed a path to a vaccine in record-breaking speed with quality and safety at the forefront, from signing an agreement with BioNTech in April to the vaccine receiving the first Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) a mere eight months later.

Read more


Internal Medicine

Inflammation & Immunology


Rare Disease



Internal Medicine

Pfizer is pursuing therapeutic candidates for debilitating conditions currently impacting millions of people worldwide, including chronic pain caused by moderate to severe osteoarthritis (OA) and nonalcoholic steatohepatitis (NASH). Learn more about Pfizer’s latest global regulatory advancements for tanezumab, a potential first-in-class treatment for people suffering from chronic OA pain, and noteworthy progress across its pipeline of novel NASH therapies. 

Read the stories

Inflammation & Immunology

People living with autoimmune diseases or other chronic inflammatory conditions often face unique and sometimes isolating challenges. Pfizer is fiercely committed to advancing scientific breakthroughs to address the unmet needs of these patients. Learn how Pfizer is progressing pipeline therapies for dermatologic conditions like alopecia areata and atopic dermatitis – all while empowering these patient communities through campaigns to foster awareness and acceptance. 

Read the stories


No matter the circumstances, advancing life-saving research for people living with cancer remains a priority for Pfizer. The U.S. FDA approved two Pfizer treatments: Braftovi®plus cetuximab for adults with metastatic colorectal cancer and Bavencio®plus chemotherapy for adults with advanced urothelial carcinoma. Beyond these approvals, Pfizer reinforced the importance of regular cancer screenings with the launch of the “Get It Done” campaign.​​​​​​​

Read the stories

Rare Disease

Pfizer’s work in rare disease continued with several promising clinical-stage developments in gene therapy. Notably, Pfizer’s therapeutic candidate for Duchenne muscular dystrophy was granted fast-track designation by the U.S. FDA. For patients living with severe hemophilia A, a groundbreaking Phase 1/2 trial exploring a potential single-dose treatment option revealed positive findings.

Read the stories


In addition to leading the charge for the development of a COVID-19 vaccine, Pfizer continued to advance vaccine candidates for underserved patient populations worldwide while expanding crucial disease surveillance and vaccine efficacy data resources for the industry at large.

Read the stories


Antimicrobial resistance (AMR) is a serious global public health threat. In 2020, Pfizer joined the AMR Action Fund as part of its ongoing commitment to alleviate the global burden of AMR through funding and development of novel antibiotics. Pfizer is also partnering with local governments and health authorities in sub-Saharan Africa to improve AMR data collection across the region.

Read the stories


Core Functions

Discover how Pfizer innovates, supplies and delivers breakthrough medicines 

Research & Development

Biosimilars hold significant potential to provide high-quality treatment options at a lower cost, including for patients suffering from life-threatening diseases like cancer. In 2020, Pfizer became the first company to launch three oncology biosimilars, collectively addressing conditions related to nine different types of cancer. In the clinical setting, Pfizer reinforced its commitment to ensuring diversity in clinical trials to help reduce health disparities of underrepresented groups.

Delivering on the Promise of Biosimilars

Driving Diversity in Our Research and Development


Pfizer Global Supply

Delivering breakthrough scientific advancements to patient communities across the world depends on the success of Pfizer’s industry-leading supply chain, spanning more than 40 Pfizer-owned sites and 200 suppliers. Demand for critical medications didn’t disappear during the pandemic, and Pfizer’s ability to rapidly solve logistical challenges brought these treatments quickly and safely to patients in need.

Pfizer and Gilead Sciences Agree to Manufacture and Supply Remdesivir

Key Medicine Supply and Public Policy During COVID-19



Ensuring medicines reach the patients who need them is a critical Pfizer guiding principle. Learn more about Pfizer’s belief in the power of strategic collaborations to help ensure that SCIENCE WILL WINTM.

Pfizer Invests in Biotechnology Innovation through the Pfizer Breakthrough Growth Initiative

Expanding Access in China Through Health Insurance Innovation


A New Era

Embracing the power of science to cure and prevent human disease

We’ve transformed our legacy to look toward the future. A time of science, compassion and breakthroughs.

Visit to learn more

Watch how Pfizer’s vigorous pursuit of scientific progress paved the way for a new emblem.

Click here to read Pfizer's top stories of 2020



Chairman and CEO Albert Bourla reflects on a year of breakthrough innovation at Pfizer

Bold Moves

Science illuminates a path forward for patients across the world


Courage, excellence, equity and joy guide all our endeavors


2020 by the numbers

COVID-19 Updates

Read the latest information about Pfizer’s COVID-19 vaccine on



Join the Conversation

Additional Information

Useful Links

The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.

Copyright © 2020-2021 Pfizer Inc.
All rights reserved

Explore our stories